Tier 3 — preclinical

The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease

Schöndorf DC, Ivanyuk D, Baden P, Sanchez-Martinez A, De Cicco S, Yu C, Giunta I, Schwarz LK, Di Napoli G, Panagiotakopoulou V, Nestel S, Keatinge M, Pruszak J, Bandmann O, Heimrich B, Gasser T, Whitworth AJ, Deleidi M
Cell reports 2018 23; 10; 2976-2988

Bibliography

PubMed
PMID 29874584
DOI
10.1016/j.celrep.2018.05.009
Funding
Indexed grant support includes European Research Council, Medical Research Council. The complete funding declaration is not specified in the accessible abstract.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignPreclinical animal study with supporting assays as applicable
ModelHuman iPSC-derived neurons and Drosophila
SampleGBA-related Parkinson’s patient-derived neurons and fly models
InterventionNR and NAD+ pathway manipulation
DurationCellular and fly aging experiments
EndpointsModel-specific physiological outcomes; Biochemical or functional measures reported in the study

What the study showed, in plain terms

NR improved mitochondrial measures in patient-derived neurons and reduced age-related neuronal loss and motor decline in flies.

Key findings

NR improved mitochondrial measures in patient-derived neurons and reduced age-related neuronal loss and motor decline in flies.

What this study can and cannot tell us

Patient-derived cells are not treated patients; the preclinical signals did not establish benefit in the later phase III Parkinson’s trial.

Related papers in the corpus

Tier 3
NAD + supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency
Hou Y et al. · Proceedings of the National Academy of Sciences of the United States of America · 2018

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology